TechNavio today published its report Global Biosimilar Market 2010“2014. The report discusses the current and future landscape of this market.
TechNavio™s report highlights that a key driver in the Global Biosimilar market is the rising number of patent expirations across leading classes of biopharmaceutical products. As biosimilar medicines are follow-on versions of original biological medicines, they can only be independently developed after the patent protection of the original product expires. Progressive patent expiry is opening up increasingly greater commercial opportunities for biosimilar products.
Commenting on the report, an analyst from TechNavio™s Healthcare team said, The manufacture of biosimilar products requires specialized capabilities, meticulous planning, highly skilled staff, and significant financial investment in equipment, technology, materials, and personnel. Therefore, the complexities and costs involved strain vendors’ resources and dilute the overall success of manufacturing biosimilar products. Thus, many vendors are increasingly turning to contract manufacturing organizations (CMOs) and clinical research organizations (CROs) that have already gained proficiency in the field of manufacturing biosimilar products.
Key findings from the report:
¢ Limited Availability of Biosimilar Products
¢ Huge Investments Required in R&D
¢ Uncertainty with Regard to Government Regulations
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key players.
TechNavio, the market research platform of Infiniti Research Ltd, publishes periodic reports on niche and emerging technologies. For further information, please visit https://www.technavio.com/content/global-biosimilar-market-2010-2014
Follow us on Twitter @ Technavio
Patent Expirations an Important Driver in the Biosimilar Market
